Deal activity in the fourth quarter represented a 24% increase in volume and a 102.8% increase in value relative to the third quarter of 2013. Relative to the fourth quarter of 2012, deal volume declined by 29.5%; however, deal value represented an increase of 106.8%. On an annual basis, deal volume in 2013 represented a modest decline of 11.6%, while deal value increased 45.8% relative to 2012. The increase in deal value in 2013 is due primarily to two initial public offerings (IPOs) in the first quarter of 2013 and a particularly strong fourth quarter.
This issue of Pharmaceutical and Life Sciences Deals Insights Quarterly brings you PwC’s perspective on deal activity in the industry and features the following:
Market update: A summary of M&A deals and trends for the previous quarter.
Market spotlight: This issue focuses African countries which represent some of the world’s fastest-growing economies, and have an increased focus on consumer-oriented sectors and investment in the pharmaceutical and life sciences industry.
Strategy corner: Tips and insights on different aspects of deal making; tax planning is a critical component of deal integration and can provide substantial cash savings to acquires.